References
- Fardel O , LecureurV , GuillouzoA . The P-glycoprotein multidrug transporter . Gen. Pharmacol.27 ( 8 ), 1283 – 1291 ( 1996 ).
- Haufroid V . Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition . Curr. Drug Targets12 ( 5 ), 631 – 646 ( 2011 ).
- Cascorbi I . Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs . Pharmacol. Ther.112 ( 2 ), 457 – 473 ( 2006 ).
- Li YH , WangYH , LiY , YangL . MDR1 gene polymorphisms and clinical relevance . Yi Chuan Xue Bao33 ( 2 ), 93 – 104 ( 2006 ).
- Bodor M , KellyEJ , HoRJ . Characterization of the human MDR1 gene . AAPS J.7 ( 1 ), E1 – E5 ( 2005 ).
- Dessilly G , ElensL , PaninNet al. ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines . PLoS ONE9 ( 3 ), e91555 ( 2014 ).
- Gregers J , GreenH , ChristensenIJet al. Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia . Pharmacogenom. J.15 ( 4 ), 372 – 379 ( 2015 ).
- Woodahl EL , YangZ , BuiT , ShenDD , HoRJ . Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein . J. Pharmacol. Exp. Ther.310 ( 3 ), 1199 – 1207 ( 2004 ).
- Gurney H , WongM , BalleineRLet al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype . Clin. Pharmacol. Ther.82 ( 1 ), 33 – 40 ( 2007 ).
- Dohse M , ScharenbergC , ShuklaSet al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib . Drug Metab. Dispos.38 ( 8 ), 1371 – 1380 ( 2010 ).
- Hegedus C , Ozvegy-LaczkaC , ApatiAet al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties . Br. J. Pharmacol.158 ( 4 ), 1153 – 1164 ( 2009 ).
- Skoglund K , MorenoSB , BaytarM , JonssonJI , GreenH . ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro . Pharmacogenom. Pers. Med.6 , 63 – 72 ( 2013 ).
- Miura M . Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia . Biol. Pharm. Bull38 ( 5 ), 645 – 654 ( 2015 ).
- Picard S , TitierK , EtienneGet al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia . Blood109 ( 8 ), 3496 – 3499 ( 2007 ).
- Capron A , MouradM , De MeyerMet al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation . Pharmacogenomics11 ( 5 ), 703 – 714 ( 2010 ).
- Elens L , CapronA , KerckhoveVVet al. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation . Pharmacogenet. Genomics17 ( 10 ), 873 – 883 ( 2007 ).
- Zheng Q , WuH , YuQet al. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis . Pharmacogenom. J.15 ( 2 ), 127 – 134 ( 2015 ).
- Vivona D , BuenoCT , LimaLTet al. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib . Blood Cells Mol. Dis.48 ( 2 ), 132 – 136 ( 2012 ).
- Ma L , RuanL , LiuH , YangH , FengY . ABCB1 C3435T polymorphism is associated with leukemia susceptibility: evidence from a meta-analysis . Onco Targets Ther.8 , 1009 – 1015 ( 2015 ).
- Dulucq S , BouchetS , TurcqBet al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia . Blood112 ( 5 ), 2024 – 2027 ( 2008 ).
- Au A , Aziz BabaA , GohASet al. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients . Biomed. Pharmacother.68 ( 3 ), 343 – 349 ( 2014 ).